Concepedia

Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma

Elisa Tavanti, Valeria Sero, Stefano Vella, Marilù Fanelli, Francesca Michelacci, Lorena Landuzzi, Giovanna Magagnoli, Rogier Versteeg, Piero Picci, Claudia Maria Hattinger,

British Journal of Cancer · 2013 · 38 citations · 22 references

DOIFull text

Open access

Abstract

Aurora kinase-A and -B represent new candidate therapeutic targets for osteosarcoma. In vitro analysis of the Aurora kinases inhibitors VX-680 and ZM447439 indicated in VX-680 a new promising drug of potential clinical usefulness in association with conventional osteosarcoma chemotherapeutic agents.

References

22

Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores

Claire Ditchfield, Victoria Johnson, Anthony Tighe et al. · The Journal of Cell Biology · 2003 · 1.2K citations · Full text

, , +16

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

Elizabeth A. Harrington, David Bebbington, Jeffrey R. Moore et al. · Nature Medicine · 2004 · 948 citations · Full text

, , +11

The Aurora Kinase Inhibitor VX-680 Induces Endoreduplication and Apoptosis Preferentially in Cells with Compromised p53-Dependent Postmitotic Checkpoint Function

Farid Gizatullin, Yao Yao, Victor Kung et al. · Cancer Research · 2006 · 177 citations · Full text

Molecular characterization of commonly used cell lines for bone tumor research: A trans‐European EuroBoNet effort

Laura Ottaviano, Karl‐Ludwig Schaefer, Melanie Gajewski et al. · Genes Chromosomes and Cancer · 2009 · 173 citations · Full text

Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1®

Robert W. Robey, Suneet Shukla, Elizabeth M. Finley et al. · Biochemical Pharmacology · 2008 · 160 citations · Full text

, , +7